Holen Sie sich die Stockscreener-App
2.095
2.56%
-0.0551
Handel nachbörslich:
2.22
0.125
+5.97%
Schlusskurs vom Vortag:
$2.1501
Offen:
$2.4
24-Stunden-Volumen:
6,516
Relative Volume:
0.65
Marktkapitalisierung:
$25.31M
Einnahmen:
$10.96M
Nettoeinkommen (Verlust:
$-7.02M
KGV:
-3.2734
EPS:
-0.64
Netto-Cashflow:
$-3.72M
1W Leistung:
-5.20%
1M Leistung:
-14.84%
6M Leistung:
-43.74%
1J Leistung:
-64.79%
1-Tages-Spanne:
$2.095
$2.40
1-Wochen-Bereich:
$2.095
$2.53
52-Wochen-Spanne:
$2.00
$6.75
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Firmenname
Collplant Biotechnologies Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CLGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
2.095 | 25.31M | 10.96M | -7.02M | -3.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-02-17 | Eingeleitet | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Aktie (CLGN) Neueste Nachrichten
Collplant stock hits 52-week low at $2.14 amid market challenges By Investing.com - Investing.com South Africa
Collplant stock hits 52-week low at $2.14 amid market challenges - Investing.com India
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevan - GuruFocus
FDA Animal Testing Phase-Out: How CollPlant's BioInk Tech Could Revolutionize Drug Safety Studies - Stock Titan
Collplant stock hits 52-week low at $2.47 amid market challenges By Investing.com - Investing.com South Africa
Collplant stock hits 52-week low at $2.47 amid market challenges - Investing.com India
D. Boral Capital Reaffirms “Buy” Rating for CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Collplant plans clinical trials for dermal filler and advances regenerative implants - MSN
Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation - simplywall.st
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven? - Yahoo
CollPlant Biotechnologies (CLGN) to Release Earnings on Thursday - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2024 Earnings Call Transcript - Insider Monkey
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highl - GuruFocus
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ... By GuruFocus - Investing.com Canada
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Decline in Short Interest - Defense World
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - StreetInsider.com
Earnings call transcript: Collplant Biotechnologies Q4 2024 misses forecasts - Investing.com India
CollPlant Biotechnologies Reports 2024 Financial Results - TipRanks
CollPlant’s Earnings Call: Mixed Outlook Amid Innovations - TipRanks
SEC Form 20-F filed by CollPlant Biotechnologies Ltd - Quantisnow
Collplant Biotechnologies Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Collplant stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia
Collplant stock hits 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
What To Expect From CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings - GuruFocus
Collplant Biotechnologies Ltd expected to post a loss of 28 cents a shareEarnings Preview - TradingView
CollPlant Biotechnologies (CLGN) to Release Quarterly Earnings on Wednesday - Defense World
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION - Quantisnow
Analyzing Anteris Technologies Global (NASDAQ:AVR) & CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Collplant stock hits 52-week low at $3.07 amid market challenges By Investing.com - Investing.com South Africa
Collplant stock hits 52-week low at $3.07 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $3.24 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $3.24 amid market challenges By Investing.com - Investing.com South Africa
Israel-based CollPlant expands distribution for VergenixSTR in Europe and Asia - BSA bureau
CollPlant expands VergenixSTR distribution in Europe and Asia By Investing.com - Investing.com Australia
CollPlant expands European and Asian distribution of soft tissue repair matrix - Yahoo Finance
CollPlant Expands Vergenix STR Distribution Across Europe And Asia - Nasdaq
Medical Breakthrough: CollPlant's Tendon Treatment Enters 4 New MarketsWhy It Matters - StockTitan
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia - PR Newswire
CollPlant secures U.S. patent for dermal filler - Investing.com India
CollPlant secures U.S. patent for dermal filler By Investing.com - Investing.com Australia
CollPlant Biotechnologies Provides a Corporate Update - PR Newswire
Tissue Engineering Market: Key Player Profiles, Industry US$ - openPR
CollPlant Biotechnologies (NASDAQ:CLGN) Earns Buy Rating from D. Boral Capital - Defense World
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Pathfinder Cell Therapy (OTCMKTS:PFND) - Defense World
Finanzdaten der Collplant Biotechnologies Ltd-Aktie (CLGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):